Welcome to our dedicated page for Perrigo Co Plc SEC filings (Ticker: PRGO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking Perrigo’s global self-care operations means sorting through FDA correspondence, European labelling rules, and dozens of product-recall footnotes scattered across hundreds of pages. Whether you’re checking how inflation squeezed infant-formula margins or comparing store-brand versus branded revenue, the raw SEC data can feel overwhelming.
Stock Titan distills every Perrigo annual report 10-K simplified, each Perrigo quarterly earnings report 10-Q filing, and any Perrigo 8-K material events explained into concise, plain-English highlights. Our AI maps line items to the questions professionals actually ask—“What did Perrigo spend on quality remediation?” or “How did international currency swings hit EPS?”—and flags risk language automatically. Receive Perrigo Form 4 insider transactions real-time, monitor Perrigo executive stock transactions Form 4, and review the Perrigo proxy statement executive compensation without manual searches. For professionals intent on understanding Perrigo SEC documents with AI, our platform layers contextual definitions over GAAP terms and links directly to source exhibits.
Looking for Perrigo insider trading Form 4 transactions ahead of a product launch? Need a quick Perrigo earnings report filing analysis that separates North American from international self-care trends? Or simply want Perrigo SEC filings explained simply so you can brief clients in minutes? Every document arrives within seconds of hitting EDGAR, paired with AI-powered summaries, key-metric tables, and historical comparisons. Spend more time assessing how Perrigo’s affordable OTC strategy drives cash flow and less time sifting through PDFs.
Perrigo Company plc (PRGO) filed a Form 4 on 14 Jul 2025 detailing routine equity-award activity by Chief Executive Officer and Director Patrick Lockwood-Taylor. On 10 Jul 2025, the executive exercised 28,326 Restricted Stock Units (code M) at an implied value of $27.27 per share, converting them into ordinary shares. To satisfy statutory tax withholding requirements, 14,234 shares were simultaneously disposed of (code F) at the same price.
Following the transactions, Lockwood-Taylor’s direct ownership rose to 81,352 ordinary shares, and he retains 28,325 unvested RSUs that will continue to vest in equal annual tranches through July 2026. The activity did not involve an open-market purchase or sale; it reflects standard vesting and tax-settlement mechanics under the company’s long-term incentive plan. While the net increase of roughly 14 k shares marginally strengthens insider alignment, it is generally viewed as neutral from a market-moving standpoint.
Perrigo Company plc (NYSE: PRGO) has signed a definitive Master Sale and Purchase Agreement dated 13 July 2025 to divest its Dermacosmetics branded business in Northern Europe, the Netherlands and Poland to Kairos Bidco AB, an investment vehicle managed by an affiliate of KKR. The transaction covers 100 % of the shares of Aco Hud Nordic AB and ancillary production, packaging and distribution assets.
Transaction economics: Kairos will pay €300 million in cash at closing, subject to customary working-capital, inventory, debt and cash adjustments. Perrigo is also eligible for up to €27 million of contingent consideration tied to performance milestones over a three-year period. Post-closing, Perrigo will provide transition services for a fee.
Timing & conditions: Closing is targeted for Q1 2026 and is contingent on (i) antitrust and other regulatory approvals, (ii) completion of agreed pre-closing restructurings, (iii) works-council consultations in certain jurisdictions and (iv) consummation of KKR’s separate acquisition of Karo Healthcare. Either party may terminate if the deal is not completed within 18 months.
Key covenants: Until closing, Perrigo must operate the Dermacosmetics business in the ordinary course, seek Kairos’s consent for certain actions, enter into non-compete and non-solicitation agreements, and continue marketing investment. Standard reps, warranties and indemnities apply; certain confidential schedules are omitted.
Strategic context: The sale further rationalises Perrigo’s portfolio after earlier divestitures (Rx, HRA Rare Diseases, Hospital & Specialty) and adds liquidity that can be redeployed toward core consumer-self-care operations or debt reduction. Management disclosed the deal via Form 8-K (Item 1.01) and a press release (Exhibit 99.1).
Perrigo Company plc (PRGO) – Form 4 insider filing: Executive Vice President & President of CSCI, Roberto Khoury, reported two transactions dated 8 July 2025.
- Disposition: Khoury disposed of 5,205 ordinary shares (Table I, coded “D”). No price information was supplied in the excerpt.
- Acquisition (equity award): He received 2,211 Restricted Stock Units (RSUs) (Table II, coded “A”). Each RSU converts to one ordinary share and vests in three equal annual instalments beginning 8 July 2026.
Following the transactions, Khoury directly owns the newly granted 2,211 RSUs; the filing does not disclose his remaining ownership of ordinary shares beyond the figures above. The activity is routine executive equity compensation combined with a modest share sale, providing limited insight into fundamental performance but useful for monitoring insider sentiment and potential dilution.
Liberty Global Ltd. (Nasdaq: LBTYK) filed a Form 8-K to disclose that its Belgian subsidiary Telenet BV and related guarantors have amended and restated their long-standing senior secured Credit Agreement, first signed in 2007. The new Supplemental Agreement, executed on 30 June 2025, introduces several structural changes designed to streamline liquidity management and extend tenor.
- Revolving Facility consolidation: The previous Revolving Facilities A & B are collapsed into a single tranche with a new final maturity of 31 May 2029.
- Incremental liquidity: Aggregate revolving commitments rise by €30.0 million (≈ US$35.3 million) through the accession of a new lender.
- Sustainability amendments: Clause 12.13 (Sustainability Adjustments) is revised, signalling an increased link between pricing and ESG performance, although exact KPIs are not detailed in the filing.
The amendment maintains The Bank of Nova Scotia as Facility Agent and KBC Bank NV as Security Agent; all obligors remain wholly-owned within the Liberty Global/Telenet structure, leaving recourse unchanged. Exhibits 4.1 and related XBRL files provide the full legal text. No financial statements accompany the filing, and no immediate draw is disclosed, so the change primarily enhances available liquidity and simplifies covenant tracking without materially altering leverage today.
FAQ
What is the current stock price of Perrigo Co Plc (PRGO)?
What is the market cap of Perrigo Co Plc (PRGO)?
What products does Perrigo offer?
How has Perrigo evolved over the years?
What is Perrigo's core business model?
Which markets are key to Perrigo's global presence?
How does Perrigo differentiate itself from competitors?
What recent innovations has Perrigo introduced?
How does Perrigo maintain its commitment to affordable healthcare?
What strategic initiatives support Perrigo's business transformation?
